Carlsmed, Inc. Cash Flow Conversion Efficiency
Carlsmed, Inc. cash flow conversion efficiency. Based on the latest financial reports, Carlsmed, Inc. (CARL) has a cash flow conversion efficiency ratio of -0.087x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.36 Million) by net assets ($84.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Carlsmed, Inc. (2023–2025)
Cash flow conversion efficiency of Carlsmed, Inc. from 2023 to 2025. This chart illustrates how Carlsmed, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Carlsmed, Inc. stock price today for real-time trading data and today's change.
Carlsmed, Inc. Cash Flow Conversion Ratio Explained
Carlsmed, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Carlsmed, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carlsmed, Inc. ranked by their cash flow conversion efficiency. Also see CARL market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianjin Saixiang Technology Co Ltd
SHE:002337
|
0.025x |
|
Israel Land Development Company Co Ltd
TA:ILDC
|
0.013x |
|
Songz Automobile Air Conditioning Co Ltd
SHE:002454
|
0.014x |
|
Heidelberger Druckmaschinen Aktiengesellschaft
F:HDD
|
-0.009x |
|
Gigasolar Materials
TWO:3691
|
-0.036x |
|
Shenzhen Huakong Seg Co Ltd
SHE:000068
|
0.070x |
|
XMax Inc.
NASDAQ:XMAX
|
-0.016x |
|
Epigral Ltd.
NSE:EPIGRAL
|
0.120x |
Annual Cash Flow Conversion Efficiency for Carlsmed, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of Carlsmed, Inc. from 2023 to 2025. Review CARL free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $98.87 Million | $-28.98 Million | -0.293x | -181.29% |
| 2024-12-31 | $-70.63 Million | $-25.47 Million | 0.361x | -4.85% |
| 2023-12-31 | $-46.13 Million | $-17.48 Million | 0.379x | -- |
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and … Read more